Olympus is set to buy Stryker's OP-1 product portfolio, which includes the OP-1 bone growth putty and OP-1 implant, for $60 million. Stryker said the deal is "aligned with strategic objectives for both companies," and it plans to spend a part of its R&D budget for the product line on other research initiatives that "offer the potential for greater shareholder returns."

Full Story:

Related Summaries